Chemical Property of azane;dichloroplatinum
Chemical Property:
- Appearance/Colour:Orange-yellow to deep yellow solid or powder
- Melting Point:340 °C (dec.)(lit.)
- PSA：24.72000
- Density:3.7 g/cm3
- LogP:2.02430
- Storage Temp.:Store at RT
- Solubility.:Soluble in DMF. Insoluble in most common solvents
- Water Solubility.:<0.1 g/100 mL at 19℃
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:2
- Rotatable Bond Count:0
- Exact Mass:298.955598
- Heavy Atom Count:5
- Complexity:2.8
- Purity/Quality:
-
99% *data from raw suppliers
Cisplatin *data from reagent suppliers
Safty Information:
- Pictogram(s):
T
- Hazard Codes:T
- Statements:
45-25-41-60-46-42/43-36/37/38
- Safety Statements:
53-26-39-45-99-36/37/39-22
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:N.N.Cl[Pt]Cl
- Recent ClinicalTrials:Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
- Recent EU Clinical Trials:A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
- Recent NIPH Clinical Trials:Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma
-
Description
Cisplastin is an non-organic platinum-containing drug with alkylating properties. It causes
cross-linking of DNA and RNA chains. In particular, it has been shown, that cisplastin, like
other alkylating agents, bind primarily at N7 of two neighboring deoxyguanylates to DNA,
which inhibits its replication. It is only used intravenously. It is highly reactive with carcinomas of the testicles, ovaries, heat, neck, spleen, lungs, and so on. Cisplatin is a platinum-containing compound that acts as a DNA-crosslinking agent and interferes with replication and transcription, culminating in apoptosis. It forms intra- and interstrand crosslinks with DNA with intrastrand guanine-to-guanine or guanine-to-alanine links accounting for the majority of DNA binding. Cisplatin halts the cell cycle at the G2/M phase in vitro and is active against murine tumors transplanted into mice and in mouse xenograft models, including a reduction in tumor growth in a model of squamous cell carcinoma of the head and neck when administered at doses ranging from 7.5 to 12.5 mg/kg. Cisplatin also inhibits the RecA recombinase of M. tuberculosis (IC50 = 2 μM), blocking protein splicing and cell growth. Formulations containing cisplatin have been used, alone and in combination therapy, in the treatment of a variety of cancers.
-
Uses
Used as an antineoplastic Cisplatin is a cytostatic agent and it is used to treat various
cancer types, including cancer of ovary, testis, lung, head,
neck, bladder, neuroblastoma, and nephroblastoma, and
Hodgkin’s disease and non-Hodgkin lymphoma. muscle relaxant (skeletal) antitumor agent
-
Indications
Cisplatin (Platinol) is an inorganic coordination complex
with a broad range of antitumor activity. It is especially
useful in the treatment of testicular and ovarian
cancer. It binds to DNA at nucleophilic sites, such as the
N7 and O6 of guanine, producing alterations in DNA
structure and inhibition of DNA synthesis. Adjacent
guanine residues on the same DNA strand are preferentially
cross-linked. This platinating activity is analogous
to the mode of action of alkylating agents. Cisplatin also
binds extensively to proteins. It does not appear to be
phase specific in the cell cycle.
-
Therapeutic Function
Antitumor
-
Clinical Use
Cisplatin, combined with bleomycin and vinblastine
or etoposide, produces cures in most patients with
metastatic testicular cancer or germ cell cancer of the
ovary. Cisplatin also shows some activity against carcinomas
of the head and neck, bladder, cervix, prostate,
and lung.
-
Drug interactions
Potentially hazardous interactions with other drugs
Aldesleukin: avoid concomitant use.
Antibacterials: increased risk of nephrotoxicity
and possibly ototoxicity with aminoglycosides,
capreomycin, polymyxins or vancomycin.
Antipsychotics: avoid with clozapine, increased risk
of agranulocytosis.
Cytotoxics: increased risk of ototoxicity with
ifosfamide; increased pulmonary toxicity with
bleomycin and methotrexate.
